Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Reason--Imagine--Act: Closed-Loop LLM Decision Making with World Models for Autonomous Driving
arXiv:2605.24004v1 Announce Type: new Abstract: Large language models (LLMs) are promising for autonomous driving, but semantics-only decision policies can yield physically unsafe behavior in dynamic traffic. Existing methods either perform online language reasoning without explicit dynamics verification or use world models mainly in offline pipelines, leaving a gap between semantic intent and physical feasibility at decision time. We propose Reason--Imagine--Act (RIA), a closed-loop framework
-
Oncogene - Issue - nature.com science feeds
-
STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4
Oncogene, Published online: 01 April 2026; doi:10.1038/s41388-026-03752-6STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4
STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4
Oncogene, Published online: 01 April 2026; doi:10.1038/s41388-026-03752-6
STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Lung cancer as a global health challenge: Multidimensional biomarker research and therapeutic advances
Int J Cancer. 2026 Mar 13. doi: 10.1002/ijc.70419. Online ahead of print.ABSTRACTLung cancer, the leading cause of global cancer-related mortality, is categorized into small-cell and non-small-cell subtypes. The heterogeneous non-small-cell lung cancer group is further subcategorized primarily into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each underpinned by distinct molecular alterations. Although traditional serum biomarkers aid in subtype differentiation and treatmen
Lung cancer as a global health challenge: Multidimensional biomarker research and therapeutic advances
Int J Cancer. 2026 Mar 13. doi: 10.1002/ijc.70419. Online ahead of print.
ABSTRACT
Lung cancer, the leading cause of global cancer-related mortality, is categorized into small-cell and non-small-cell subtypes. The heterogeneous non-small-cell lung cancer group is further subcategorized primarily into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each underpinned by distinct molecular alterations. Although traditional serum biomarkers aid in subtype differentiation and treatment monitoring, their utility is limited by challenges such as poor specificity due to inflammatory confounders and the difficulty of dynamically tracking therapeutic resistance. Recent advances have identified emergent subtype-specific biomarkers that reflect metabolic reprogramming, epigenetic dysregulation, stemness signatures, and interactions within the immune microenvironment. By integrating analytes such as ctDNA, exosomal RNAs, and urinary DNA with multi-analyte panels and advanced imaging, liquid biopsies offer a promising avenue to enhance early detection accuracy, prognostication, and dynamic therapy monitoring. Nevertheless, the clinical adoption is hindered by several challenges, including incomplete validation, the need for technical standardization, intratumoral heterogeneity, and inter-ethnic variability. The convergence of artificial intelligence (AI)-enhanced multi-omics with biomarker-guided therapeutics represents a transformative strategy with the potential to overcome resistance, mitigate ethnic disparities, and ultimately transform lung cancer into a chronic, manageable disease. Therefore, prioritizing clinically validated AI-integrated platforms is pivotal to achieve precision oncology.
PMID:41826059 | DOI:10.1002/ijc.70419
-
Omics In Lung
-
Lung cancer as a global health challenge: Multidimensional biomarker research and therapeutic advances
Int J Cancer. 2026 Mar 13. doi: 10.1002/ijc.70419. Online ahead of print.ABSTRACTLung cancer, the leading cause of global cancer-related mortality, is categorized into small-cell and non-small-cell subtypes. The heterogeneous non-small-cell lung cancer group is further subcategorized primarily into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each underpinned by distinct molecular alterations. Although traditional serum biomarkers aid in subtype differentiation and treatmen
Lung cancer as a global health challenge: Multidimensional biomarker research and therapeutic advances
Int J Cancer. 2026 Mar 13. doi: 10.1002/ijc.70419. Online ahead of print.
ABSTRACT
Lung cancer, the leading cause of global cancer-related mortality, is categorized into small-cell and non-small-cell subtypes. The heterogeneous non-small-cell lung cancer group is further subcategorized primarily into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each underpinned by distinct molecular alterations. Although traditional serum biomarkers aid in subtype differentiation and treatment monitoring, their utility is limited by challenges such as poor specificity due to inflammatory confounders and the difficulty of dynamically tracking therapeutic resistance. Recent advances have identified emergent subtype-specific biomarkers that reflect metabolic reprogramming, epigenetic dysregulation, stemness signatures, and interactions within the immune microenvironment. By integrating analytes such as ctDNA, exosomal RNAs, and urinary DNA with multi-analyte panels and advanced imaging, liquid biopsies offer a promising avenue to enhance early detection accuracy, prognostication, and dynamic therapy monitoring. Nevertheless, the clinical adoption is hindered by several challenges, including incomplete validation, the need for technical standardization, intratumoral heterogeneity, and inter-ethnic variability. The convergence of artificial intelligence (AI)-enhanced multi-omics with biomarker-guided therapeutics represents a transformative strategy with the potential to overcome resistance, mitigate ethnic disparities, and ultimately transform lung cancer into a chronic, manageable disease. Therefore, prioritizing clinically validated AI-integrated platforms is pivotal to achieve precision oncology.
PMID:41826059 | DOI:10.1002/ijc.70419
-
cs.AI, q-bio.NC updates on arXiv.org
-
JavisDiT: Joint Audio-Video Diffusion Transformer with Hierarchical Spatio-Temporal Prior Synchronization
arXiv:2503.23377v2 Announce Type: replace-cross Abstract: This paper introduces JavisDiT, a novel Joint Audio-Video Diffusion Transformer designed for synchronized audio-video generation (JAVG). Based on the powerful Diffusion Transformer (DiT) architecture, JavisDiT simultaneously generates high-quality audio and video content from open-ended user prompts in a unified framework. To ensure audio-video synchronization, we introduce a fine-grained spatio-temporal alignment mechanism through a Hie